Avoid common mistakes on your manuscript.
Two recent reports in Intensive Care Medicine raise important questions regarding a potential mortality hazard of extracorporeal blood purification for the treatment of septic shock.
Garbero et al. report the results of the COMPACT-2 trial investigating high volume coupled plasma filtration and adsorption (CPFA) in 115 patients suffering from septic shock [1]. The study was prematurely determined due to a potential harmful effect of CPFA as mortality in the intensive care unit (ICU) was 54% in the treatment and 29% in the control group. In particular, early mortality after 3 days was more than twice as high in the CPFA group and a significant treatment dose—response effect on mortality even suggested a putative causal relationship.
Just a few days earlier, Wendel-Garcia and colleagues reported equally concerning results in a propensity score matched analysis, studying hemoadsorption by means of the CytoSorb adsorber in 96 patients suffering from severe refractory septic shock [2]. In May of this year, a small trial of patients affected by coronavirus disease 2019 (COVID-19) with severe acute respiratory distress syndrome (ARDS) undergoing extracorporeal membrane oxygenation (ECMO) therapy noted a mortality increase of 58% in patients randomized to receive additive cytokine adsorption, albeit as secondary outcome [3].
Alarmingly, in the short period of a few months, three rigorously conducted investigations, sharing the same intervention, have suggested that indiscriminate removal of circulating mediators from the blood might be unexpectedly harmful in patients with septic shock. Potential effectors of this observation require careful consideration. Both CPFA and full blood hemoadsorption have the potential to remove both injurious and protective substances involved in the pathophysiology of sepsis. It is, therefore, conceivable that extraction of protective factors diminishes beneficial physiological responses such as immune homeostasis restoration, endothelial integrity re-establishment as well as a reduction of coagulopathy.
Earlier this year, we reported results of a randomized controlled trial exploring additive therapeutic plasma exchange (TPE) in patients with severe refractory septic shock, finding rapid hemodynamic improvement following this intervention [4]. In contrast to CPFA and CytoSorb hemoadsorption, TPE combines two therapeutic measures in a singular intervention [5]. It effectively removes injurious mediators such as proinflammatory cytokines, endothelial destabilizing factors (e.g. Angiopoietin-2, Heparanase-1) and molecules involved in intravascular coagulation (e.g. von-Willebrand factor) (Fig. 1). Simultaneously, the exchange of septic plasma with that from healthy donors leads to a replenishment of protective but consumed factors involved in anti-inflammatory processes (e.g. immunoglobulins), in endothelial stabilization (e.g. Angiopoietin-1, Heparanase-2) and in anti-coagulation (e.g. Antithrombin-III, Protein C, ADAMTS-13). Larger randomized studies investigating additive use of TPE in septic shock are under way.
Given the unmet medical need to improve our therapeutic strategies against the pathological host response in sepsis, we believe that the appealing concept of blood purification should endure under the pervasive Hippocrates umbrella “First do not harm”. In conceptualizing future studies, we suggest to consider options that not only unselectively remove but also replace consumed counterbalancing factors.
References
Garbero E, Livigni S, Ferrari F, Finazzi S, Langer M, Malacarne P et al (2021) High dose coupled plasma filtration and adsorption in septic shock patients. Results of the COMPACT-2: a multicentre, adaptive, randomised clinical trial. Intensive Care Med. https://doi.org/10.1007/s00134-021-06501-3
Wendel Garcia PD, Hilty MP, Held U, Kleinert EM, Maggiorini M (2021) Cytokine adsorption in severe, refractory septic shock. Intensive Care Med. https://doi.org/10.1007/s00134-021-06512-0
Supady A, Weber E, Rieder M, Lother A, Niklaus T, Zahn T et al (2021) Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial. Lancet Respir Med 9(7):755–762
David S, Bode C, Putensen C, Welte T, Stahl K (2021) Adjuvant therapeutic plasma exchange in septic shock. Intensive Care Med 47(3):352–354
Knaup H, Stahl K, Schmidt BMW, Idowu TO, Busch M, Wiesner O et al (2018) Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers. Crit Care 22(1):285
Funding
Open Access funding enabled and organized by Projekt DEAL.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Stahl, K., Wendel-Garcia, P.D., Bode, C. et al. Unraveling the secret of re-balancing homeostasis in sepsis: a critical view on extracorporeal blood purification modalities. Intensive Care Med 48, 130–132 (2022). https://doi.org/10.1007/s00134-021-06560-6
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00134-021-06560-6